A ranar 15 ga Afrilu, 2022, an kammala samar da matukin jirgi na Lecardipine hydrochloride babban zobe a lokaci guda, kuma ƙarfin samarwa na yanzu shine 5Mt/ wata.

Hasashen kasuwa:
Akwai mutane sama da miliyan 200 da ke fama da cutar hawan jini a kasar Sin, kuma ana samun sabbin masu kamuwa da cutar hawan jini miliyan 10 a kowace shekara, yawancinsu ba a kula da su ba, lamarin da ke haddasa yawaitar matsalolin hauhawar jini kamar shanyewar jiki, da mace-mace a kasar Sin a duk shekara a cikin 3. miliyan masu fama da cututtukan zuciya, 50% suna da alaƙa da hauhawar jini, kuma farashin jiyya na cututtukan zuciya ya kai yuan biliyan 309.8 kowace shekara.Dalilin rashin kula da marasa lafiya ba wai kawai ya kamata a inganta fahimtar marasa lafiya game da hauhawar jini da matsalolinsa ba, har ma da yawancin marasa lafiya da ke buƙatar shan magungunan rayuwa ba su da kyau kuma ba za su iya shan magani a kowace rana ba, amma wannan kuma ya nuna cewa. Kasuwar magungunan antihypertensive tana da yuwuwar haɓakawa.Idan aka kwatanta da irin waɗannan kwayoyi, locarbodipine hydrochloride yana da ƙarfin zaɓi na jijiyoyin jini.Kayan sa na musamman na lipophilic yana sa shi jinkiri kuma yana dawwama yana tasirin antihypertensive Tasirin atherogenic, musamman dacewa ga masu fama da hauhawar jini tare da atherosclerosis, yana da ƙimar aikace-aikacen asibiti mai girma da fa'idar kasuwa.